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 Statement of Translational Relevance: Tumor vascularity is thought to be the conduit 
to metastatic dissemination. This has led to great interest in targeting angiogenesis, 
resulting in novel therapies such as bevacizumab (Avastin), an antibody targeted against 
the vascular endothelial growth factor, VEGF. However, the clinical impact of these 
drugs on overall survival in melanoma patients is limited, suggesting that VEGF may not 
be the only factor modulating angiogenesis. Here, we present data which show that 
VEGF signaling is decreased during aging and superseded by sFRP2, a factor that 
aggressively guides angiogenesis in older patients. In the presence of sFRP2 therefore, 
tumors are less responsive to anti-VEGF therapies, which may underlie the lack of 
efficacy of anti-VEGF therapies in the elderly, while pointing to the fact that younger 
patients may actually benefit from bevacizumab.  Understanding how age-related 
changes in the tumor microenvironment govern response to targeted therapies can 





Purpose: Angiogenesis is thought to be critical for tumor metastasis. However, inhibiting 
angiogenesis using antibodies such as bevacizumab (Avastin), has had little impact on 
melanoma patient survival. We have demonstrated that both angiogenesis and 
metastasis are increased in older individuals, and therefore sought to investigate if there 
was an age-related difference in response to bevacizumab, and if so, what the 
underlying mechanism could be.  
Experimental Design: We analyzed data from the AVAST-M trial of 1343 melanoma 
patients treated with bevacizumab to determine if there is an age-dependent response to 
bevacizumab. We also examined the age-dependent expression of VEGF and its 
cognate receptors in melanoma patients, while using syngeneic melanoma animal 
models to target VEGF in young vs old mice. We also examined the age-related pro-
angiogenic factor sFRP2 and if it could modulate response to anti-VEGF therapy.  
Results: We show that older patients respond poorly to bevacizumab, whereas younger 
patients show improvement in both disease-free and overall survival. We find that 
targeting VEGF does not ablate angiogenesis in an aged mouse model, while sFRP2 
promotes angiogenesis in vitro and in young mice. Targeting sFRP2 in aged mice 
successfully ablates angiogenesis, while the effects of targeting VEGF in young mice 
can be overcome by increasing sFRP2. 
Conclusions: VEGF is decreased during aging, thereby reducing response to 
bevacizumab. Despite the decrease in VEGF, angiogenesis is increased, due to an 
increase in sFRP2 in the aged tumor microenvironment. These results stress the 




The progression of melanoma to distant metastatic sites increases with age. Age 
is the single most prognostic factor for patient survival1, and older patients are at 
increased risk for the development of frequently incurable visceral metastases2,3. 
However, a mechanistic basis for age-related changes in tumor dissemination that 
underlie such inferior clinical outcomes is not fully understood4. The formation of visceral 
metastases requires tumor access to the systemic circulation, and in some cancers, low 
levels of angiogenesis are highly prognostic of distant metastatic-free survival5,6.  
Angiogenesis is accomplished by the recruitment of endothelial cells to the tumor 
microenvironment, and this is thought to be initiated by tumor cell secretion of factors 
such as the vascular endothelial growth factor, VEGF. Other factors including platelet 
derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) are also thought 
to contribute to VEGF-mediated angiogenesis. Melanoma cells have been shown to 
increase their production of all of these factors7,8. VEGF is thought to be a key factor in 
the angiogenic pathway, binding to its cognate receptors, and driving signaling that 
results in endothelial cell proliferation, and migration. However, in melanoma, 
angiogenesis is complex, and VEGF itself is not thought to be a predictor of poor 
prognosis in melanoma, as there is no change in the levels of VEGF secreted by 
metastatic vs primary melanoma lesions9,10. Further, while the analyses of human 
melanoma lesions have shown a strong correlation between angiogenesis and the ability 
of a melanoma lesion to transition from a radial to a vertical growth phase11, other 
indicators of vascularity are not as clear. For example, microvessel density is not thought 
to correlate to patient prognosis in melanoma in some studies12, where others show that 
it does 13,14. Finally, and further complicating these issues is the fact that melanoma cells 
themselves can form vascular networks, in a process known as vascular mimicry15,16.  
Despite the complicated landscape of angiogenesis in cancer, bevacizumab, an 
antibody that is targeted against multiple isoforms of VEGF, has been tested in 
metastatic cancers of multiple origins, and approved for the treatment of some. 
Bevacizumab, better known under its trade name Avastin, was tested in melanoma in a 
clinical trial known as the AVAST-M melanoma trial17,18. In this multi-center, randomized, 
phase III trial, 1343 patients were randomized into those who received Avastin for a 
year, vs. those who were placed under observation. With a minimum of 5 years follow-
up, there were no significant differences for distant-metastasis free survival, or overall 
survival and only a slight improvement in disease-free intervals. These analyses did not 
consider age as a variable. Our data show that advanced age of the patient can predict 
their response to therapy, either in a negative manner, such as an attenuated response 
to BRAF/ MEK inhibitors19 or in a positive manner, such as a stronger response to 
immunotherapy20,21. In that context, we wanted to know if the age of the patient could 
also predict their response to bevacizumab. Further to that, we have previously shown 
that the aged dermal fibroblast secretome has multiple effects on melanoma progression 
including increases in genomic instability, resistance to targeted therapy, and 
metastasis. One of the factors responsible for increased metastatic dissemination is the 
secreted frizzled-related protein 2 (sFRP2) which is a non-canonical Wnt family member 
that is elevated in the serum of aged melanoma patients22. In cancer models such as 
breast cancer, sFRP2 stimulates angiogenesis. This function of sFRP2 occurs through a 
β-catenin-independent pathway, via activated calcineurin/NFAT23, and has been shown 
to increase angiogenesis in other cancer models. Targeting sFRP2 with a monoclonal 
antibody has been shown to overcome angiogenesis in breast cancer models23, and our 
own data have shown that angiogenesis in established melanoma tumors in aged mice 
can also be targeted by antibodies against sFRP222, but we have not fully explored the 
impact of age on angiogenesis. In this study, therefore, we examined the hypothesis that 
the age of the melanoma patient could predict response to Avastin, and that the 




To determine the effects of aging on angiogenesis, we first stained whole tumor 
samples from young and aged melanoma patients for CD31, to assess blood vessel 
density throughout the tumor. We found that the percentage of CD31 coverage within 
tumors was significantly increased in patients over the age of 65 as compared to 
patients under the age of 65 (Figure 1A, additional representative staining, Supplemental 
Figure 1A). Next, we examined neoangiogenesis and lymphangiogenesis in a syngeneic 
mouse model of melanoma. Yumm1.7 cells
24
, derived from the 
BrafV600E/Cdkn2a−/−/Pten−/− mouse model of melanoma25 were injected into the dermis of 
young (8 weeks) or aged (52 weeks) C57/BL6 mice and serial sections of primary 
tumors were stained for CD105 and LYVE1.  Previous studies of ours have shown that 
CD31 is increased within an aged melanoma mouse tumors22; however, while CD31 is a 
commonly utilized pan-endothelial cell marker, it does not distinguish LYVE-1 positive 
lymphatic endothelium from CD105-positive blood microvascular endothelium26.  
Moreover, CD105 is thought to be a more specific marker than CD31 for malignancy-
associated blood microvasculature27,28 and has a stronger prognostic significance than 
traditional vascular markers29.  In a cohort of genetically identical mice inoculated with 
identical melanoma cells, tumors in the aged microenvironment showed increased 
CD105-positive blood microvascular density (Fig. 1B, additional representative staining, 
Supplemental Figure 1B) with no age-related differences in LYVE1-positive lymphatic 
vessel density (Fig. 1C).  To determine if age-related changes in the fibroblast 
secretome may account for differences in tumor angiogenesis, adult human dermal 
microvascular endothelial cells (HMVECs) were exposed to the conditioned media of 
dermal fibroblasts from young (<45 years) and aged (>55 years) healthy donors from the 
Baltimore Longitudinal Study of Aging30.  The secretome of aged fibroblasts significantly 
increased the proliferative index of HMVECs (Fig. 1D) as well as the formation of 
capillary structures in a previously validated in vitro tubule formation assay (Fig 1E,F)31.  
In contrast, HMVECs treated with young fibroblast conditioned media or unconditioned 
media formed less complex capillary structures.  Such data support the role of the aged 
dermal fibroblast secretome as a proangiogenic microenvironment.   
To determine if these changes in angiogenesis were driven by classical 
angiogenic drivers, specifically VEGF, we queried the importance of VEGF signaling in 
the aged microenvironment. Intriguingly, increased patient age was associated with 
decreased expression of VEGF (Fig. 2A) as well as its two primary receptors, VEGFR1 
(Fig. 2B) and VEGFR2 (Fig. 2C) in an age-stratified analysis of melanoma patient gene 
expression in TCGA. This decrease in VEGF with age led us to hypothesize that age-
related differences in response to bevacizumab (AvastinTM), an anti-VEGF antibody, 
might exist. We tested this hypothesis by analyzing data from the AVAST-M randomized 
controlled phase III trial evaluating the role of adjuvant bevacizumab in patients with 
resected melanoma at high risk of recurrence17. Higher VEGF scores in this group also 
correlated with improved survival, potentially due to the availability of target for the drug 
(Fig. 2D). Next, we performed a post-hoc trial analysis for the interaction between age 
and response to treatment. Younger patients who received adjuvant bevacizumab had a 
significantly longer disease-free interval (age <45 years: HR 0.71, 95% CI 0.53-0.96), 
while there was no impact of therapy on disease recurrence in older patients (age >65 
years: HR 1.00, 95% CI 0.72-1.38) (Fig 2E).  Similar patterns of treatment effect trended 
strongly for the outcome of overall survival as well (Supplemental Fig. 2A).   Finally, 
given that BRAF status has been associated with response to Avastin18, we examined 
the data with an emphasis on BRAF status, and age.  We found that the effect of Avastin 
is significant for young patients harboring the BRAF mutation, although the young 
patients who were BRAF WT showed a similar non-significant trend. The fact that the 
data did not reach significance could also be due to the fact that far fewer young patients 
are BRAF WT. Older patients showed no benefit from bevacizumab regardless of their 
BRAF status (Supplemental Figure 2B). We also queried the TCGA database for the 
expression of VEGF and its receptors according to BRAF status and age. We found 
significant correlations between age and VEGF and most of its receptors, but for the 
most part, these did not separate out by BRAF status (Supplemental Figure 2C), 
supporting the observations in Supplemental Figure 2B.  We found that the effect of 
Avastin is significant for young patients who are BRAF mutant, although the young 
patients who are BRAF WT respond in a similar, albeit non-significant manner.  Given 
that there was no therapeutic benefit for BRAF mutant patients of older age ranges, we 
hypothesize that age and not BRAF status is the predominant determinant of 
response to Avastin.  
 Since increased age-related angiogenesis could not be explained by VEGF 
changes, and older patients did not appear to benefit from adjuvant bevacizumab, we 
hypothesized that other factors were driving angiogenesis in the elderly. sFRP2 is an 
established proangiogenic factor23,32 and we have previously demonstrated that sFRP2 
is an important component of the aged dermal fibroblast secretome, and is associated 
with increased CD31 staining in tumors in aged mice22. The treatment of HMVECs with 
recombinant sFRP2 was sufficient to increase cell proliferation (Fig. 3A) and its addition 
to young conditioned media increased capillary formation in vitro to levels observed with 
treatment with aged conditioned media (Fig. 3B,C).  HMVEC treatment with aged 
conditioned media and a neutralizing α-SFRP2 antibody was sufficient to inhibit in vitro 
angiogenesis (Fig 3B, lower panels).   
These data suggested that sFRP2 may take over as the predominant pro-
angiogenic factor during aging. To further support this, analysis of  melanoma samples 
in the TCGA data base demonstrates that there is a positive association between CD105 
and sFRP2, while VEGF expression inversely correlates with CD105 expression (Fig. 
3D,E.  Further, we observed that sFRP2 is increased in ulcerated tumors, which have 
large amounts of blood vessels, whereas VEGF showed no such correlation to 
ulceration (Supplemental Fig 3A, B). We assessed the impact of sFRP2 on neo-
angiogenesis in vivo, specifically by assessing CD105 staining. We injected Yumm1.7 
cells into the dermis of young (8 weeks) C57/BL6 mice treated with recombinant sFRP2 
(rsFRP2) (200ng/ml, tail vein, twice weekly) or PBS control. In parallel, we also injected 
Yumm1.7 cells into the dermis of aged (52 weeks) C57/BL6 mice treated with anti-
sFRP2 antibody (1mg/kg, tail vein, once weekly) or with IgG2a control. Subsequently, 
we stained these tumors for intra-tumoral CD105-positive microvascular density, which 
was significantly greater in young mice treated with rsFRP2 (Fig. 3F) with no difference 
in lymphatic vessel density (Fig. 3G). Neutralizing sFRP2 in aged mice was sufficient to 
reduce CD105-positive microvascular density, without any quantifiable changes in 
lymphatic vessel density. Notably, there was no difference in tumor size with rsFRP2 or 
α-sFRP2 treatment (Supplemental Fig. 3C,D), nor increased human melanoma cell 
proliferation with rsFRP2 treatment in vitro (Supplemental Fig. 3E), supporting a 
selective effect on endothelial and not melanoma cell proliferation, and excluding any 
potential bias between tumor size and vascularity. Finally, we also confirm previous data 
showing that treating young mice with recombinant sFRP2 drives melanoma cell 
metastasis from the skin to the lung, and that inhibiting sFRP2 in aged mice inhibits 
metastatic progression to the lung (Supplemental Fig. 3F,G). Together these data 
showed that the observed age-related increase in angiogenesis was likely due to 
sFRP2.  
To test the hypothesis that sFRP2 superseded VEGF as the predominant 
angiogenic factor during aging, we examined serial sections of primary Yumm1.7 
allografts from untreated young or aged C57/BL6 mice for their VEGF and sFRP2 status. 
As observed with the human data, increasing age led to a decrease in VEGF 
expression, and we also observed a parallel increase in sFRP2 expression (Figure 
4A,B). To test if increased sFRP2 could impact response to anti-VEGF therapies, we 
treated young mice with an antibody against VEGF-A (bevacizumab is species specific 
and cannot neutralize murine VEGF-A33) in the presence and absence of sFRP2. Anti-
VEGF reduced angiogenesis in mouse tumors in young mice in vivo; however, when 
administered in the presence of rsFRP2, there was no reduction in angiogenesis, and 
indeed blood vessel density was increased, just as it is in the presence of sFRP2 alone 
(Figure 4C,D, additional representative staining in Supplemental Figure 4). Tumor size 
was unaffected by treatment (Figure 4E), and there was little toxicity with the treatments 
(Fig. 4F). This confirmed our hypothesis that when sFRP2 levels increase, as they do in 
aging, anti-VEGF therapy is no longer effective, and provides a basis for the observed 
lack of benefit from adjuvant bevacizumab in older patients recruited to the AVAST-M 
trial. Overall, our data suggest that angiogenesis is increased in the aged tumor 
microenvironment, but that this angiogenesis is an sFRP2 rather than VEGF driven 
process. Since VEGF is no longer the predominant angiogenic factor in older patients, 
targeting this pathway may have less impact in older versus younger patients.  
 
Discussion   
Angiogenesis in melanoma is complex, and we show in this study that age-
related changes in the tumor microenvironment further limit the efficacy of current 
therapies targeting angiogenesis. We have shown that angiogenesis and growth are 
uncoupled in melanoma, such that tumors in aged mice have more angiogenesis, and 
metastasize at much great rates, but actually grow far more slowly than tumors in young 
mice22.  This may be due to the fact that the factors that drive angiogenesis in aging 
(e.g., sFRP2) also increase other factors such as Wnt5A which we have shown 
previously is a powerful suppressor of growth and proliferation, and promotes a slow-
cycling phenotype in melanoma allowing cells to resist therapy34. Angiogenesis thus 
becomes only one of a myriad of changes wrought by the aged microenvironment, and 
we have shown that these changes encompass everything from biophysical changes35 
to immune microenvironment changes21 to changes in lipid secretion and uptake19. In 
addition to sFRP2, we have found other factors in the secretome of aged fibroblasts that 
may also have an impact on angiogenesis. These include RARRES1 and CLU. 
Intriguingly, RARRES1 has been shown to inhibit VEGF36, further supporting our theory 
that VEGF levels are decreased during aging. Whether or not this affects sFRP2 levels, 
or whether sFRP2 can induce RARRES1 remains an open question, and a topic of 
further study. We also identified CLU as elevated in the aged secretome. This first 
seemed counter-intuitive as CLU or clusterin, has been shown to increase angiogenesis 
in ovarian cancer, however, the role of CLU is dependent upon VEGF37. It is possible 
that the increase in CLU is a futile attempt to compensate for VEGF decreases. 
Therefore, the significance of clusterin in age and sFRP2-induced angiogenesis is 
somewhat unclear. The roles of both of RARRES and CLU, and their potential regulation 
by sFRP2 and/ or other age-related factors remain interesting areas to pursue.  
 One area that we did not explore in the current study is the important area of 
blood vessel integrity and pericyte coverage. Helfrich et al38 have shown that increased 
pericyte coverage can confer resistances to anti-VEGF treatment strategies, and this is 
consistent with our observed increases in CD31 staining in aged human patients. This 
study used the MT/RET mouse model of melanoma to uncover the changes that occur in 
the stabilization of blood vessels, and intriguingly, this mouse model is an excellent 
model in which to study aging-related changes.  MT-RET transgenic mice are 
engineered to express the human ret transgene in melanocytes controlled by the mouse 
metallothionein-I promoter-enhancer39.  These mice are reported to spontaneously 
develop melanomas metastasizing to lymph nodes, lungs, brain, kidney and spleen.  
This process involves the development of skin melanosis (100% just after birth), benign 
melanocytic tumors (100% after 6 months), and metastatic melanoma (65-70% in mice 
18 months old).  The Helfrich study examined pericyte coverage in lesions with high vs 
low levels of angiogenesis, but it is unclear whether these studies took into account the 
age at which the highly angiogenic versus less angiogenic tumors developed, and if 
there was an age-related component of angiogenesis in this model. It is important to 
note that in this study, they, like us, observed that angiogenesis was uncoupled from 
tumor size.   
While currently available anti-angiogenic therapies target the VEGF pathways, 
age-dependent loss in VEGF, in tandem with increases in alternative angiogenic 
pathways, such as sFRP2, may limit efficacy of Bevacizumab in older melanoma 
patients, but could potentially still be an appropriate treatment in young patients. The 
AVAST-M trial demonstrated that adjuvant bevacizumab improved the disease-free 
interval compared with observation alone in the overall recruited patient population, 
although this early benefit did not translate to an overall survival gain.  The trial was not 
designed to adjust for patient age in the randomization process, thus these post-hoc 
data must be interpreted with caution. However, there does appear to be a striking 
association between patient age and risk of relapse after adjuvant bevacizumab. 
Additional data also suggest that using bevacizumab in conjunction with immunotherapy 
(specifically ipilimumab) results in an improved immune microenvironment40, potentially 
increasing response to immunotherapy. Given our data and others showing that older 
patients already have an enhanced response to immunotherapy, this observation 
warrants further investigation.  
It remains to be determined whether sFRP2 can be targeted in human melanoma 
patients.  Alternatively, drug therapies targeting the downstream mediators of sFRP2 
may be additional avenues for exploration.  The aged secretome is characterized by 
disturbances in multiple proteins including increases in Wnt5A, which can also activate 
NFAT via CAMKII/calcineurin pathways41,42, suggesting sFRP2 and Wnt5A may work in 
concert during aging to increase angiogenesis.  In fact, similar increases in angiogenesis 
were observed following treatment with rWnt5a in vitro (Supplemental Fig. 5A) and in 
Wnt5a-overexpressing Yumm1.7 tumors (Supplemental Fig. 5B).  As calcineurin 
inhibitors (e.g., tacrolimus) have already been approved for human use, this may be a 
preferred strategy for inhibiting age-related angiogenesis by blocking a convergence of 
NFAT-driven mechanisms, and indeed have been suggested before43. In conclusion, the 
aged tumor microenvironment promotes hematogenous melanoma dissemination, where 
loss of VEGF is offset with overexpression of proangiogenic sFRP2.  Together, these 
data provide therapeutic rationale to consider patient age in decisions regarding 
selection of therapy. 
 
Methods 
Cell lines and culture conditions 
Dermal fibroblast cell lines were obtained from Biobank at Coriell Institute for 
Medical Research. The fibroblasts were cultured in DMEM (Invitrogen) supplemented 
with 10% FCS and 4mM L-glutamine.  HMVEC-dBlAd cells were obtained from Lonza 
and cultured in EGM-2MV media (CC-3202, Lonza).  Murine Yumm1.7 melanoma cells 
were cultured in DMEM supplemented with 10%FCS and 4mM L-glutamine. WM35 
melanoma cells were maintained in in MCDB153 (Sigma)/L-15 (Cellgro; 4:1 ratio) 
supplemented with 2% FBS and 1.6 mmol/L CaCl2 (tumor growth media).   All the cell 
lines were cultured at 37°C in 5% CO2.  Short tandem repeat profiling was done for 
melanoma cells and compared against our internal control of over 200 melanoma cell 
lines as well as control lines such as HeLa and 293T and the results are available upon 
request. Mycoplasma testing was carried out using a Lonza MycoAlert assay at the 
University of Pennsylvania Cell Center Services.  
 
Cellular Proliferation assay 
In a 24 well plate, 5000 cells were plated in triplicate per day of measurement. 
Cells were treated with recombinant sFRP2 (200ng/ml, #6838-FR, R&D) without any 
replacement of addition of fresh medium. Every 2-3 days, cells were counted using 
hemocytometer and the total cell number in the well was recorded. Graphs were plotted 
using percent proliferation based on day 0.  
 
Tubule formation assay 
HMVEC-dBlAd cells were purchased from Lonza as stated. Cells were thawed 
and allowed to grow for two passages before the assay was performed as previously 
described44. Briefly, 48 well plates were covered with 90μl Matrigel (concentration 
>10mg/ml; BD Biosciences, #354234) and allowed to solidify at room temperature for 30 
minutes. HMVEC cells were aliquoted at 50,000 cells per well, resuspended in 400l of 
media and added dropwise to each well. Young and aged media were concentrated at 
~10x using 3000 Da MWCO filters (UFC900324, Amicon, EMD Millipore) and 
reconstituted to 1x with DMEM containing 10% FCS. Reagents were purchased from 
rsFRP2 (200ng/ml, 6838-FR, R&D Systems), Wnt5a (200ng/ml, 645-WN, R&D 
Systems), anti-sFRP2 neutralizing antibody (15g/ml, MABC539, EMD Millipore). bFGF 
at 35ng/ml is used as positive control. Plates were incubated at 37°C for 12-18 hours. 
Tubules will start to appear at 10-12 hours and start to contract over time. Images were 
taken at various intervals to determine optimal tubule formation. 
 
Immunohistochemistry 
Patient samples were collected under IRB exemption approval (protocol 
EX21205258-1). FFPE sections were deparaffinized using xylene followed by 
rehydration through series of alcohol washes and finally PBS. Heat-mediated antigen 
retrieval was performed using citrate based retrieval buffer (Vector Labs, H-3300). 
Samples were blocked in peroxide blocking buffer (Thermo Scientific), followed by 
protein block (Thermo Scientific) and incubated in appropriate antibody at 4°C overnight 
in a humidified chamber. Following day, samples were washed and incubated with a 
biotinylated secondary antibody (Thermo Scientific) followed by Streptavidin-HRP 
incubation. Samples were then washed in PBS and incubated in 3-amino-9-ethyl-1-
carboazole (AEC) chromogen and counterstained with Mayer’s hematoxylin, rinsed in 
dH2O and mounted in Aquamount. For mouse samples to be incubated with mouse 
antibodies, samples were blocked for an additional hour with mouse on mouse block 
(MKB-2213, Vector Labs).  Primary antibodies used were as follows: CD105/Endoglin 
(1:100, MAB1320, R&D Systems), Lyve-1 (1:50, ab14917, abcam). sFRP2 (1:100, 
ab137560, abcam), VEGF (human: 1:100, M727329-8, DAKO; mouse: 1:50, sc7269, 
Santa Cruz Biotechnology), CD31 (1:100, GA61061-2, DAKO), mCherry (1:500, NBP2-
25157, Novus Biologicals), biotinylated Wnt5A (500 ng/mL, BAF645, R&D Systems). 
 
Immunofluorescence 
Samples were fixed in 4% paraformaldehyde for 20 minutes followed by 1 hour 
treatment with blocking buffer (0.2% each of triton-x, BSA, gelatin and casein and 0.02% 
sodium azide). Cells were incubated in primary antibody and incubated overnight at 4°C.  
Following day, cells were washed in PBS and incubated with appropriate secondary 
antibodies (Alexa fluor series, Invitrogen, 1:2000) at room temperature for 1 hour. Cells 
were washed in PBS, incubated with DAPI (Invitrogen, 1:10,000) and mounted in 
Prolong Gold anti-fade reagent (Invitrogen). Images were captured on a Leica TCS SPII 
scanning laser confocal system. Primary antibodies used were as follows: Ki67 (1:400, 
#9027, Cell Signaling), sFRP2 (1:100, MAB6838, R&D Systems), biotinylated Wnt5A 
(500 ng/mL, BAF645, R&D Systems). 
 
In vivo allograft assay 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) (IACUC #112503X_0, IACUC #112510X_0) and were performed in 
an Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) accredited facility. Yumm1.7 (1 x 105 cells) overexpressing mCherry or 
mCherry-Wnt5a were injected subcutaneously into aged (52 weeks) and young (8 weeks 
old) C57/BL6 mice (#556, Charles River). Mice were treated as follows with rsFRP2 
(200ng/ml, tail vein, twice weekly), anti-sFRP2 antibody (1mg/kg, tail vein, once weekly), 
anti-VEGF (1mg/kg, tail vein, once weekly) or PBS, IgG2a and goat IgG  as control. 
Tumor sizes were measured every 3-4 days using digital calipers, and tumor volumes 
were calculated using the following formula: volume = 0.5 x (length x width2). Time-to-
event (survival) was determined by a 5-fold increase in baseline volume (~1000 mm3) 
and was limited by the development of skin necrosis. Mice were euthanized and primary 
tumors and lungs harvested. Half of the tissue was embedded in paraffin and half in 
optimal cutting temperature compound (O.C.T, Sakura, Japan City) and flash frozen for 
sectioning. Lungs were sectioned and stained with mCherry (NBP2-25157, Novus 
Biologicals) to determine melanoma metastasis. All reagents injected in live mice were 
tested for endotoxin levels at University of Pennsylvania Cell Center Services using The 
Associates of Cape Cod LAL test.  
 
TCGA database analysis 
The RNAseq and Clinical dataset for skin cutaneous melanoma45 was 
downloaded from The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/). 
Normalized mRNA expression was analyzed by quartiles.  Patient ages were grouped 
into categories (<45, 45-65, and >65 years). High vs low categories (sFRP2 and VEGFa) 
were stratified based on the 25 percentile of high or low expressing tumor samples. 
 
Lentiviral production and infection 
Wnt5a overexpression plasmid was prepared by cloning Wnt5a from pLNCX2 
plasmid published previously34 into lentiviral pLU-MCS-IRES-mCherry plasmid. 
Sequencing based verification of all plasmids was performed at the Genomics facility at 
The Wistar Institute. Lentiviral production was performed according to the protocol 
suggested by the Broad Institute. Briefly, 293T cells are plated at 70% confluency and 
co-transfected with shRNA plasmid and the lentiviral packaging plasmids (pCMV-
dR8.74psPAX2, pMD2.G). pLKO.1 empty vector was used as a control. For 
transduction, cells were treated with lentivirus overnight and allowed to recover for 24 
hours before selection using puromycin (1μg/ml). 
 
Statistical analyses 
 For in vitro studies, a Student t test or Wilcoxon rank-sum test (Mann–Whitney) 
was performed for two-group comparison. Estimate of variance was performed, and 
parameters for the t test were adjusted accordingly using Welch's correction. ANOVA or 
Kruskal–Wallis test with post-hoc Bonferroni's or Holm–Sidak's adjusted P values was 
used for multiple comparisons. For in vivo studies, repeated measures ANOVA was 
calculated between samples. The Holm–Sidak correction was performed. Kaplan-Meier 
and Cox regression was utilized for univariate and multivariate survival analyses, 
respectively  For other experiments, Graphpad/Prism8 was used for plotting graphs and 
statistical analysis. Data was represented as ±SEM. Significance was designated as 
follows: *, P < 0.05; **, P < 0.01; and ***, P < 0.001. 
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Figures and  Legends 
 
Figure 1. Aging increases angiogenesis in melanoma.  A. Representative CD31 
staining in young and aged human melanoma samples (100X, n=28, under 65yo; 
n=12,over 65yo). B. Representative CD105 immunohistochemistry of Yumm 1.7 
melanoma tumors five weeks following intradermal injection in young (8 weeks) and 
aged (52 weeks) C57/BL6 mice (n=10/arm; magnification 400x),with quantification of 
intratumoral blood vessel density shown in the graph; C. Representative LYVE1 
immunohistochemistry of Yumm 1.7 melanoma tumors five weeks following intradermal 
injection in young (8 weeks) and aged (52 weeks) C57/BL6 mice (n=10/arm; 
magnification 400x), with quantification of intratumoral lymphatic vessel density shown in 
the graph. D. HMVECs were treated for 24 hours with conditioned media from young or 
aged dermal fibroblasts and stained for Ki67 by immunofluorescence, with quantification 
of Ki67-positive HMVECs per high power field (HPF) shown in the graph; E. 
Representative light-field images of HMVEC tubule formation following treatment with 
conditioned media from young or aged dermal fibroblasts or unconditioned fibroblast 
media; F. Quantification of number of tubule nodes per high power field.  
 
Figure 2. Relationship of VEGF to age and response to bevacizumab. A. Age-
stratified TCGA analysis of VEGFA mRNA expression of cutaneous melanoma (n=465); 
B. Age-stratified TCGA analysis of VEGFR1 (FLT1) mRNA expression of cutaneous 
melanoma (n=465); C. Age-stratified TCGA analysis of VEGFR2 (KDR) mRNA 
expression of cutaneous melanoma (n=465). D. Correlation of high vs. low VEGF 
expression to survival in AVASTM patients; E, Age-stratified analysis of disease-free 
survival in melanoma patients randomized to bevacizumab therapy or observation 
(n=1,324).  
 
Figure 3. sFRP2 increases angiogenesis during aging.  A. Proliferation assay of 
HMVECs grown with standard growth media with the addition of rSFRP2 (200 ng/mL) or 
PBS control; **p<0.01; ***p<0.001, ****p<0.0001; B. Representative light-field images of 
HMVEC tubule formation following treatment with conditioned media from young 
fibroblasts with rSFRP2 or aged fibroblasts with neutralizing α-SFRP2 antibody; C. 
Quantification of number of tubule nodes per high power field in B. D. Quantification of 
CD105 positivity in sFRP2 low vs. high tumor in TCGA samples. E. Quantification of 
CD105 positivity in VEGF low vs. high tumor in TCGA samples. F. Representative 
CD105 immunohistochemistry of primary Yumm 1.7-mcherry murine tumors in young 
C57BL/6 mice treated with PBS or rSFRP2, and aged mice treated with α-SFRP2 
antibody or IgG2aκ control and quantification of CD105-positive vessel density; G. 
Representative LYVE1 immunohistochemistry of primary Yumm 1.7-mcherry murine 
tumors in young C57BL/6 mice treated with PBS or rSFRP2, and aged mice treated with 
α-SFRP2 antibody or IgG2aκ control and quantification of LYVE1-positive vessel 
density. 
 
Figure 4: sFRP2 treatment overcomes response to anti-VEGF. A. Representative 
immunohistochemistry of VEGF and sFRP2 staining in tumors in young and aged mice; 
B. Quantification of staining in A, based on the H-score calculated by percent of tumor 
positive, and intensity of stain. C. Representative CD105 immunohistochemistry of 
primary Yumm 1.7 mcherry murine tumors in young C57BL/6 mice treated with PBS or 
rsFRP2, in the presence of the anti-VEGFA antibody, or an IgG control. D. Quantification 
of staining in C. E. Yumm 1.7 cells were implanted in mice and then mice were treated 
with antibody treatments as indicated, and tumor growth was measured. F. Mouse 
weight in grams after indicated treatments, beginning 12 days after tumor inoculation.  
 
 
Supplemental Figure Legends 
 
Supplemental Figure 1. Representative immunohistochemistry images. A. 
Representative images of CD31 staining in young and aged human melanoma patients. 
B. Representative images of CD105 staining in young and aged mouse tumors.  
 
Supplemental Figure 2. Avastin Response in Patients. A. Age-stratified analysis of 
overall survival in melanoma patients randomized to bevacizumab therapy or 
observation (n=1,324). B. Forest plot showing the association between BRAF, age and 
treatment response for disease free interval in Avastin treated patients. C. Expression of 
VEGF and its receptors according to BRAF status and age using TCGA data.  
 
Supplemental Figure 3: sFRP2 treatment does not affect tumor growth, but does 
increase invasion. A. Quantification of sFRP2 expression in ulceration positive vs 
negative tumors in TCGA samples. B. Quantification of VEGF expression in ulceration 
positive vs negative tumors in TCGA samples. C. Tumor growth curves of Yumm1.7-
mCherry murine tumors in young C57/BL6 mice treated with PBS or rSFRP2; D. Tumor 
growth curves of Yumm1.7-mCherry murine tumors in aged C57/BL6 mice treated with 
α-SFRP2 antibody or IgG2aκ control; E. Proliferation assay of WM35 melnaoma cells 
grown with standard growth media with the addition of rsFRP2 (200ng/mL) or PBS 
control. F. mCherry staining of Yumm1.7-mCherry cells in mouse lung that metastasized 
from subcutaneous injection in young mice treated with either PBS or rsFRP2 or G. aged 
mice treated with IgG control, or anti-sFRP2 antibody. 
 
Supplemental Figure 4. Representative images of CD105 staining in young mice 
treated with anti-VEGF, rsFRP2, or the combination. Representative CD105 
immunohistochemistry of primary Yumm 1.7 mcherry murine tumors in young C57BL/6 
mice treated with PBS or rsFRP2, in the presence of the anti-VEGFA antibody, or an IgG 
control as indicated. 
 
Supplemental Figure 5. Wnt5A expression can also increase angiogenesis. A. 
Representative light-field images of HMVEC tubule formation following treatment with 
young fibroblast conditioned media and PBS or rWnt5a (200ng/mL); B. Quantification of 
number of tubule nodes per high power field; C. Representative CD105 
immunohistochemistry of control or Wnt5a-overexpressing Yumm1.7 tumors in young 
C57/BL6 mice (n=4 per arm); D. Quantification of CD105-positive vessels/HPF. 
 




